Release date: 2017-07-11 Source: Bio-Exploration Liraglutide injection pen is a medication used to treat type 2 diabetes.
It is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps
regulate blood sugar levels by increasing insulin secretion and
decreasing glucagon production. The injection pen is pre-filled with
liraglutide and is administered once a day subcutaneously (under the
skin). It is important to follow the instructions provided by the
healthcare provider on how to use the injection pen and to monitor blood
sugar levels regularly. Common side effects may include nausea,
vomiting, diarrhea, headache, and dizziness. Liraglutide Injection Pen,Injectable Liraglutide Pen,Reusable Liraglutide Pen Injector,Rhgh Pen Injector Shanghai Enjosim Medical Technology Co., Ltd , https://www.enjosimmedical.com
Pain in patients with chemotherapy - hair loss
It is well known that hair loss is a problem that many cancer patients have to face during chemotherapy: some patients may become thinner due to chemotherapy; others may gradually fall off completely, or the volume may become thinner. To a certain extent, this will affect the patient's psychology (a lot of hair loss makes many beauty people feel inferior and sad), which indirectly affects the patient's sensitivity to treatment.
At the end of 2015, the FDA approved for the first time a special cooling cap (DigniCap) for breast cancer chemotherapy patients. On the one hand, it has the effect of cooling the blood vessels on the scalp, reducing the effect of chemotherapy drugs reaching the hair follicles; on the other hand, the cold temperature also reduces the activity of the hair follicles, slowing down cell division and making it less affected by chemotherapy. In clinical trials (122 patients with stage I and II breast cancer chemotherapy), more than 66% of patients with early-stage breast cancer had less than half of their hair loss after using Dignicap.
Applications: From breast cancer to all solid tumors
After two years, the FDA has recently expanded the range of applications for this type of cooling cap, which can be applied to all solid tumor patients. This is the first FDA-approved cooling cap for all solid tumors. 
Â
first! This new FDA approved hat is suitable for all solid tumor patients to reduce hair loss during chemotherapy
Source: biological exploration / Author: / 2017-07-11  0  1  188
Pain in patients with chemotherapy - hair loss
It is well known that hair loss is a problem that many cancer patients have to face during chemotherapy: some patients may become thinner due to chemotherapy; others may gradually fall off completely, or the volume may become thinner. To a certain extent, this will affect the patient's psychology (a lot of hair loss makes many beauty people feel inferior and sad), which indirectly affects the patient's sensitivity to treatment.
At the end of 2015, the FDA approved for the first time a special cooling cap (DigniCap) for breast cancer chemotherapy patients. On the one hand, it has the effect of cooling the blood vessels on the scalp, reducing the effect of chemotherapy drugs reaching the hair follicles; on the other hand, the cold temperature also reduces the activity of the hair follicles, slowing down cell division and making it less affected by chemotherapy. In clinical trials (122 patients with stage I and II breast cancer chemotherapy), more than 66% of patients with early-stage breast cancer had less than half of their hair loss after using Dignicap.
Applications: From breast cancer to all solid tumors
After two years, the FDA has recently expanded the range of applications for this type of cooling cap, which can be applied to all solid tumor patients. This is the first FDA-approved cooling cap for all solid tumors.